{"transactions":[{"id":4626589,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13398,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":4626588,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24258,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":9.39,"expiration_date":"2035-05-18","underlying":"Ordinary Shares","underlying_shares":24258},"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":4626587,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23576,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":9.49,"expiration_date":"2034-05-07","underlying":"Ordinary Shares","underlying_shares":23576},"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":4626586,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22044,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":10.95,"expiration_date":"2033-05-01","underlying":"Ordinary Shares","underlying_shares":22044},"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":4626585,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":10.15,"expiration_date":"2032-04-25","underlying":"Ordinary Shares","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":4626584,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":20.35,"expiration_date":"2031-04-26","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":4626583,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":20.66,"expiration_date":"2030-06-30","underlying":"Ordinary Shares","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":4626582,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6009,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a \"Company RSU Award\") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":4626581,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:37:27.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":58065,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. (\"Parent\"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer (\"Ordinary Share\") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the \"Per Share Cash Consideration\") and (ii) one contingent value right (a \"CVR\"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time."}],"balance_after":6009,"source":{"system":"sec-edgar","filing":"0001270734-26-000007","document":"form4-09252026_120922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000127073426000007/form4-09252026_120922.xml","form_type":"4"}},{"id":736003,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-17T01:35:54.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":13398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":13398,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001270734-26-000004","document":"form4-06172026_010650.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000127073426000004/form4-06172026_010650.xml","form_type":"4"}},{"id":736002,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-17T01:35:54.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":6009,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":64074,"source":{"system":"sec-edgar","filing":"0001270734-26-000004","document":"form4-06172026_010650.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000127073426000004/form4-06172026_010650.xml","form_type":"4"}},{"id":763500,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-26T20:15:39.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":15508,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the award of restricted stock units (\"RSUs\") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event."}],"balance_after":15508,"source":{"system":"sec-edgar","filing":"0001270734-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000127073426000002/ownership.xml","form_type":"4"}},{"id":876999,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2026-02-27T21:30:13.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":66000,"derivative":{"exercise_price":0.39,"expiration_date":"2036-02-26","underlying":"American Depositary Shares","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001193125-26-082818","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000119312526082818/ownership.xml","form_type":"4"}},{"id":1130396,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2025-05-29T20:13:39.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":4600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests as to 100% of the underlying shares on May 28, 2026."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025."}],"balance_after":4600,"derivative":{"exercise_price":4.48,"expiration_date":"2035-05-27","underlying":"Common Stock","underlying_shares":4600},"source":{"system":"sec-edgar","filing":"0000950170-25-078961","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017025078961/ownership.xml","form_type":"4"}},{"id":1138856,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-05-21T23:20:13.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":24258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":24258,"derivative":{"exercise_price":9.39,"expiration_date":"2035-05-18","underlying":"Ordinary Shares","underlying_shares":24258},"source":{"system":"sec-edgar","filing":"0001415889-25-014022","document":"form4-05212025_110510.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000141588925014022/form4-05212025_110510.xml","form_type":"4"}},{"id":1138855,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-05-21T23:20:13.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":10649,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":58065,"source":{"system":"sec-edgar","filing":"0001415889-25-014022","document":"form4-05212025_110510.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000141588925014022/form4-05212025_110510.xml","form_type":"4"}},{"id":1280172,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2025-02-06T21:30:15.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 5, 2025 grant date"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":55000,"derivative":{"exercise_price":3.16,"expiration_date":"2035-02-05","underlying":"American Depositary Shares","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-015423","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017025015423/ownership.xml","form_type":"4"}},{"id":1424126,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (right to buy)","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Vests in substantially equal monthly installments over a one year period from the February 8, 2024 grant date. As of June 8, 2024, 15,000 Share Options have vested."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":30000,"derivative":{"exercise_price":3.87,"expiration_date":"2034-02-08","underlying":"American Depository Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424125,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (right to buy)","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":false,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Vested in substantially equal monthly installments over a one year period from the February 1, 2023 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0.94,"expiration_date":"2033-02-01","underlying":"American Depository Shares","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424124,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (right to buy)","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":false,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Vested in substantially equal monthly installments over a one year period from the February 1, 2022 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":1.31,"expiration_date":"2032-02-01","underlying":"American Depository Shares","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424123,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (right to buy)","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":false,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Vested in substantially equal monthly installments over a one year period from the February 1, 2021 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":2.72,"expiration_date":"2031-02-01","underlying":"American Depository Shares","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424122,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (right to buy)","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Vested in substantially equal monthly installments over a one year period from the February 20, 2020 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":1.84,"expiration_date":"2030-02-20","underlying":"American Depository Shares","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424121,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (right to buy)","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":false,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vested in substantially equal monthly installments over a one year period from the July 23, 2019 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":3,"expiration_date":"2029-07-23","underlying":"American Depository Shares","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424120,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"sale","planned":false,"acquired":false,"shares":105244,"price":4.4298,"value":466209.8712,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Sale is due to fund administration reasons."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.360 to $4.495, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc (\"Mereo\"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnote (3) to this Form"}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424119,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":true,"shares":2071,"price":3.87,"value":8014.77,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":105244,"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424118,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":true,"shares":43485,"price":0.94,"value":40875.9,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":103173,"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424117,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":true,"shares":38953,"price":1.31,"value":51028.43,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":59688,"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424116,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":true,"shares":12418,"price":2.72,"value":33776.96,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":20735,"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424115,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":true,"shares":6492,"price":1.84,"value":11945.28,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":8317,"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424114,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":true,"shares":1825,"price":3,"value":5475.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":1825,"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1486476,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T23:18:17.000Z","date":"2024-06-07","kind":"sale","planned":false,"acquired":false,"shares":2240,"price":0.9507,"value":2129.568,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9303 to $0.965, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Delphi BioInvestments VIII, L.P. (\"DB VIII\"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-070991","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024070991/ownership.xml","form_type":"4"}},{"id":1486475,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T23:18:17.000Z","date":"2024-06-07","kind":"sale","planned":false,"acquired":false,"shares":229308,"price":0.9507,"value":218003.1156,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9303 to $0.965, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Delphi Ventures VIII, L.P. (\"DV VIII\"). Delphi Management Partners VIII, L.L.C. (\"DMP VIII\"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-070991","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024070991/ownership.xml","form_type":"4"}},{"id":1486474,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T23:18:17.000Z","date":"2024-06-06","kind":"sale","planned":false,"acquired":false,"shares":1145,"price":0.9828,"value":1125.306,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.97 to $1.0302, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Delphi BioInvestments VIII, L.P. (\"DB VIII\"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":2240,"source":{"system":"sec-edgar","filing":"0000950170-24-070991","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024070991/ownership.xml","form_type":"4"}},{"id":1486473,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T23:18:17.000Z","date":"2024-06-06","kind":"sale","planned":false,"acquired":false,"shares":117307,"price":0.9828,"value":115289.3196,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.97 to $1.0302, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Delphi Ventures VIII, L.P. (\"DV VIII\"). Delphi Management Partners VIII, L.L.C. (\"DMP VIII\"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":229308,"source":{"system":"sec-edgar","filing":"0000950170-24-070991","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024070991/ownership.xml","form_type":"4"}},{"id":1486472,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T23:18:17.000Z","date":"2024-06-05","kind":"sale","planned":false,"acquired":false,"shares":4526,"price":0.9582,"value":4336.8132,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.899 to $0.989, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Delphi BioInvestments VIII, L.P. (\"DB VIII\"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":3385,"source":{"system":"sec-edgar","filing":"0000950170-24-070991","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024070991/ownership.xml","form_type":"4"}},{"id":1486471,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T23:18:17.000Z","date":"2024-06-05","kind":"sale","planned":false,"acquired":false,"shares":463518,"price":0.9582,"value":444142.9476,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.899 to $0.989, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Delphi Ventures VIII, L.P. (\"DV VIII\"). Delphi Management Partners VIII, L.L.C. (\"DMP VIII\"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":346615,"source":{"system":"sec-edgar","filing":"0000950170-24-070991","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024070991/ownership.xml","form_type":"4"}},{"id":1491822,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T22:51:44.000Z","date":"2024-06-04","kind":"sale","planned":false,"acquired":false,"shares":3298,"price":0.9521,"value":3140.0258,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.93 to $0.9985, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Delphi BioInvestments VIII, L.P. (\"DB VIII\"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":7911,"source":{"system":"sec-edgar","filing":"0000950170-24-068969","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024068969/ownership.xml","form_type":"4"}},{"id":1491821,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T22:51:44.000Z","date":"2024-06-04","kind":"sale","planned":false,"acquired":false,"shares":337742,"price":0.9521,"value":321564.1582,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.93 to $0.9985, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Delphi Ventures VIII, L.P. (\"DV VIII\"). Delphi Management Partners VIII, L.L.C. (\"DMP VIII\"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":810133,"source":{"system":"sec-edgar","filing":"0000950170-24-068969","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024068969/ownership.xml","form_type":"4"}},{"id":1491820,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T22:51:44.000Z","date":"2024-06-03","kind":"sale","planned":false,"acquired":false,"shares":3488,"price":1.0007,"value":3490.4416,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9643 to $1.06, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Delphi BioInvestments VIII, L.P. (\"DB VIII\"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":11209,"source":{"system":"sec-edgar","filing":"0000950170-24-068969","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024068969/ownership.xml","form_type":"4"}},{"id":1491819,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T22:51:44.000Z","date":"2024-06-03","kind":"sale","planned":false,"acquired":false,"shares":357256,"price":1.0007,"value":357506.0792,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9643 to $1.06, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Delphi Ventures VIII, L.P. (\"DV VIII\"). Delphi Management Partners VIII, L.L.C. (\"DMP VIII\"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":1147875,"source":{"system":"sec-edgar","filing":"0000950170-24-068969","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024068969/ownership.xml","form_type":"4"}},{"id":1491818,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T22:51:44.000Z","date":"2024-05-31","kind":"sale","planned":false,"acquired":false,"shares":1976,"price":0.954,"value":1885.104,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9308 to $0.9996, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Delphi BioInvestments VIII, L.P. (\"DB VIII\"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":14697,"source":{"system":"sec-edgar","filing":"0000950170-24-068969","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024068969/ownership.xml","form_type":"4"}},{"id":1491817,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T22:51:44.000Z","date":"2024-05-31","kind":"sale","planned":false,"acquired":false,"shares":202418,"price":0.954,"value":193106.772,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9308 to $0.9996, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Delphi Ventures VIII, L.P. (\"DV VIII\"). Delphi Management Partners VIII, L.L.C. (\"DMP VIII\"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":1505131,"source":{"system":"sec-edgar","filing":"0000950170-24-068969","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024068969/ownership.xml","form_type":"4"}},{"id":1497676,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2024-05-30T21:32:35.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":69000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 100% of the underlying shares on May 29, 2025."}],"balance_after":69000,"derivative":{"exercise_price":0.96,"expiration_date":"2034-05-28","underlying":"Common Stock","underlying_shares":69000},"source":{"system":"sec-edgar","filing":"0000950170-24-066785","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024066785/ownership.xml","form_type":"4"}},{"id":1520474,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-05-10T22:12:17.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":23576,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":23576,"derivative":{"exercise_price":9.49,"expiration_date":"2034-05-07","underlying":"Ordinary Shares","underlying_shares":23576},"source":{"system":"sec-edgar","filing":"0001415889-24-012919","document":"form4-05102024_100512.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000141588924012919/form4-05102024_100512.xml","form_type":"4"}},{"id":1520473,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-05-10T22:12:17.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":10537,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47416,"source":{"system":"sec-edgar","filing":"0001415889-24-012919","document":"form4-05102024_100512.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000141588924012919/form4-05102024_100512.xml","form_type":"4"}},{"id":1651409,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2024-02-09T21:15:24.000Z","date":"2024-02-08","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 8, 2024 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":45000,"derivative":{"exercise_price":3.87,"expiration_date":"2034-02-08","underlying":"American Depository Shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000950170-24-013271","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024013271/ownership.xml","form_type":"4"}},{"id":1877857,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2023-05-25T20:10:09.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 100% of the underlying shares on May 24, 2024."}],"balance_after":34000,"derivative":{"exercise_price":2.5,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001209191-23-032149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000120919123032149/doc4.xml","form_type":"4"}},{"id":1904231,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-05-04T22:48:34.000Z","date":"2023-05-02","kind":"grant","planned":false,"acquired":true,"shares":22044,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":22044,"derivative":{"exercise_price":10.95,"expiration_date":"2033-05-01","underlying":"Ordinary Shares","underlying_shares":22044},"source":{"system":"sec-edgar","filing":"0001415889-23-007384","document":"form4-05042023_100524.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000141588923007384/form4-05042023_100524.xml","form_type":"4"}},{"id":1904230,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-05-04T22:48:34.000Z","date":"2023-05-02","kind":"grant","planned":false,"acquired":true,"shares":9132,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":36879,"source":{"system":"sec-edgar","filing":"0001415889-23-007384","document":"form4-05042023_100524.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000141588923007384/form4-05042023_100524.xml","form_type":"4"}},{"id":2040293,"issuer":{"id":113073,"kind":"organization","name":"Calithera Biosciences, Inc.","symbol":"CALA"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-31T19:04:07.000Z","date":"2023-01-27","kind":"sale","acquired":false,"shares":1172,"price":0.3858,"value":452.1576,"ownership":{"direct":false,"nature":"Delphi\nBioInvestments VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.36 to $0.41, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities were directly held by Delphi BioInvestments VIII, L.P. (\"DBI VIII\"). DMP VIII is the general partner of DBI VIII and was deemed to have sole voting and dispositive power over the securities held by DBI VIII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VIII and were deemed to share voting and dispositive power over the securities held by DBI VIII. Such persons and entities disclaim beneficial ownership of the securities held by DBI VIII, except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-003071","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496671/000089924323003071/doc4.xml","form_type":"4"}},{"id":2040292,"issuer":{"id":113073,"kind":"organization","name":"Calithera Biosciences, Inc.","symbol":"CALA"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-31T19:04:07.000Z","date":"2023-01-27","kind":"sale","acquired":false,"shares":120161,"price":0.3858,"value":46358.1138,"ownership":{"direct":false,"nature":"Delphi Ventures VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.36 to $0.41, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities were directly held by Delphi Ventures VIII, L.P. (\"DV VIII\"). Delphi Management Partners VIII, L.L.C. (\"DMP VIII\") is the general partner of DV VIII and was deemed to have sole voting and dispositive power over the securities held by DV VIII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VIII and were deemed to share voting and dispositive power over the securities held by DV VIII. Such persons and entities disclaim beneficial ownership of the securities held by DV VIII, except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-003071","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496671/000089924323003071/doc4.xml","form_type":"4"}},{"id":2235712,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T21:20:57.000Z","date":"2022-06-10","kind":"sale","acquired":false,"shares":13,"price":6.0019,"value":78.0247,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Delphi BioInvestments VIII, L.P. (\"DB VIII\").  DMP VIII is the general partner of each of DB VIII and DV VIII.  The Reporting Person is a managing member of DMP VIII.  As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":16673,"source":{"system":"sec-edgar","filing":"0000899243-22-021957","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000089924322021957/doc4.xml","form_type":"4"}},{"id":2235711,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T21:20:57.000Z","date":"2022-06-10","kind":"sale","acquired":false,"shares":1294,"price":6.0019,"value":7766.4586,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Delphi Ventures VIII, L.P. (\"DV VIII\"). Delphi Management Partners VIII, L.L.C. (\"DMP VIII\"), is the general partner of each of DB VIII and DV VIII.  The Reporting Person is a managing member of DMP VIII.  As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":1707549,"source":{"system":"sec-edgar","filing":"0000899243-22-021957","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000089924322021957/doc4.xml","form_type":"4"}},{"id":2235710,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T21:20:57.000Z","date":"2022-06-09","kind":"sale","acquired":false,"shares":2045,"price":6.1798,"value":12637.691,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Delphi BioInvestments VIII, L.P. (\"DB VIII\").  DMP VIII is the general partner of each of DB VIII and DV VIII.  The Reporting Person is a managing member of DMP VIII.  As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":16686,"source":{"system":"sec-edgar","filing":"0000899243-22-021957","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000089924322021957/doc4.xml","form_type":"4"}},{"id":2235709,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T21:20:57.000Z","date":"2022-06-09","kind":"sale","acquired":false,"shares":209455,"price":6.1798,"value":1294390.009,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Delphi Ventures VIII, L.P. (\"DV VIII\"). Delphi Management Partners VIII, L.L.C. (\"DMP VIII\"), is the general partner of each of DB VIII and DV VIII.  The Reporting Person is a managing member of DMP VIII.  As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":1708843,"source":{"system":"sec-edgar","filing":"0000899243-22-021957","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000089924322021957/doc4.xml","form_type":"4"}},{"id":2235708,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T21:20:57.000Z","date":"2022-06-08","kind":"sale","acquired":false,"shares":3152,"price":6.5033,"value":20498.4016,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Delphi BioInvestments VIII, L.P. (\"DB VIII\").  DMP VIII is the general partner of each of DB VIII and DV VIII.  The Reporting Person is a managing member of DMP VIII.  As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":18731,"source":{"system":"sec-edgar","filing":"0000899243-22-021957","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000089924322021957/doc4.xml","form_type":"4"}},{"id":2235707,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T21:20:57.000Z","date":"2022-06-08","kind":"sale","acquired":false,"shares":322825,"price":6.5033,"value":2099427.8225,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Delphi Ventures VIII, L.P. (\"DV VIII\"). Delphi Management Partners VIII, L.L.C. (\"DMP VIII\"), is the general partner of each of DB VIII and DV VIII.  The Reporting Person is a managing member of DMP VIII.  As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":1918298,"source":{"system":"sec-edgar","filing":"0000899243-22-021957","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000089924322021957/doc4.xml","form_type":"4"}},{"id":2244627,"issuer":{"id":113073,"kind":"organization","name":"Calithera Biosciences, Inc.","symbol":"CALA"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T16:05:40.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12 of the Option vests in each monthly installment as measured from June 1, 2022, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer.  In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to the Delphi Management Partners, VIII, L.L.C. (\"DMP VIII\") LLC Agreement, the Reporting Person is deemed to hold the options for the benefit of DMP VIII, which is entitled to hold the shares upon issuance. DMP VIII may be deemed the indirect beneficial owner of such shares, and the Reporting Person is a managing member of DMP VIII and may be deemed to share voting and dispositive power over shares held by DMP VIII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein."}],"balance_after":20000,"derivative":{"exercise_price":0.2,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-22-020935","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496671/000089924322020935/doc4.xml","form_type":"4"}},{"id":2261597,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2022-05-20T20:11:10.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":23900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 100% of the underlying shares on the earlier of May 19, 2023 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc."}],"balance_after":23900,"derivative":{"exercise_price":5.65,"expiration_date":"2032-05-18","underlying":"Common Stock","underlying_shares":23900},"source":{"system":"sec-edgar","filing":"0001209191-22-030983","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000120919122030983/doc4.xml","form_type":"4"}},{"id":2288669,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2022-04-29T01:26:10.000Z","date":"2022-04-26","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":28000,"derivative":{"exercise_price":10.15,"expiration_date":"2032-04-25","underlying":"Ordinary Shares","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001415889-22-004336","document":"form4-04282022_060457.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000141588922004336/form4-04282022_060457.xml","form_type":"4"}},{"id":2288668,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-04-29T01:26:10.000Z","date":"2022-04-26","kind":"grant","acquired":true,"shares":9852,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":27747,"source":{"system":"sec-edgar","filing":"0001415889-22-004336","document":"form4-04282022_060457.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000141588922004336/form4-04282022_060457.xml","form_type":"4"}},{"id":2456076,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock","published_at":"2021-12-30T21:00:26.000Z","date":"2021-12-23","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Class A Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001213900-21-068105","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000121390021068105/ownership.xml","form_type":"4/A","original_submission_date":"2021-12-28"}},{"id":2456075,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-12-30T21:00:26.000Z","date":"2021-12-23","kind":"exercise","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001213900-21-068105","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000121390021068105/ownership.xml","form_type":"4/A","original_submission_date":"2021-12-28"}},{"id":2457808,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock","published_at":"2021-12-28T21:00:14.000Z","date":"2021-12-23","kind":"exercise","acquired":false,"shares":52500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Class A Common Stock","underlying_shares":52500},"source":{"system":"sec-edgar","filing":"0001213900-21-067726","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000121390021067726/ownership.xml","form_type":"4"}},{"id":2457807,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-12-28T21:00:14.000Z","date":"2021-12-23","kind":"exercise","acquired":true,"shares":52500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer."}],"balance_after":52500,"source":{"system":"sec-edgar","filing":"0001213900-21-067726","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000121390021067726/ownership.xml","form_type":"4"}},{"id":2670139,"issuer":{"id":113073,"kind":"organization","name":"Calithera Biosciences, Inc.","symbol":"CALA"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-14T16:05:30.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12 of the Option vests in each monthly installment as measured from June 11, 2021, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer.  In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to the Delphi Management Partners, VIII, L.L.C. (\"DMP VIII\") LLC Agreement, the Reporting Person is deemed to hold the options for the benefit of DMP VIII, which is entitled to hold the shares upon issuance. DMP VIII may be deemed the indirect beneficial owner of such shares, and the Reporting Person is a managing member of DMP VIII and may be deemed to share voting and dispositive power over shares held by DMP VIII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein."}],"balance_after":20000,"derivative":{"exercise_price":2.28,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-21-023539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496671/000089924321023539/doc4.xml","form_type":"4"}},{"id":2700615,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2021-05-21T21:35:49.000Z","date":"2021-05-21","kind":"grant","acquired":true,"shares":23900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 100% of the underlying shares on the earlier of May 21, 2022 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. (the \"Issuer\"), provided that the reporting person continues to serve as a director of the Issuer through such date."}],"balance_after":23900,"derivative":{"exercise_price":9.42,"expiration_date":"2031-05-20","underlying":"Common Stock","underlying_shares":23900},"source":{"system":"sec-edgar","filing":"0001209191-21-035030","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000120919121035030/doc4.xml","form_type":"4"}},{"id":2735711,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2021-04-29T22:15:07.000Z","date":"2021-04-27","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":6000,"derivative":{"exercise_price":20.35,"expiration_date":"2031-04-26","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001179110-21-004706","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000117911021004706/edgar.xml","form_type":"4"}},{"id":2735710,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-04-29T22:15:07.000Z","date":"2021-04-27","kind":"grant","acquired":true,"shares":9828,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":17895,"source":{"system":"sec-edgar","filing":"0001179110-21-004706","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000117911021004706/edgar.xml","form_type":"4"}},{"id":3088518,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2020-07-06T21:53:35.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest monthly over ten months of service from the date of grant and will vest in full upon the earlier of the ten-month anniversary of Dr. Pakianathan's appointment to the Board or the date of the Company's 2021 annual meeting of shareholders."}],"balance_after":5000,"derivative":{"exercise_price":20.66,"expiration_date":"2020-06-30","underlying":"Ordinary Shares","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001179110-20-008053","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000117911020008053/edgar.xml","form_type":"4"}},{"id":3088517,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2020-07-06T21:53:35.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests monthly over 24 months of service from the date of grant."}],"balance_after":12000,"derivative":{"exercise_price":20.66,"expiration_date":"2030-06-30","underlying":"Ordinary Shares","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001179110-20-008053","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000117911020008053/edgar.xml","form_type":"4"}},{"id":3088516,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-07-06T21:53:35.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":8067,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8067,"source":{"system":"sec-edgar","filing":"0001179110-20-008053","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000117911020008053/edgar.xml","form_type":"4"}},{"id":3113371,"issuer":{"id":113073,"kind":"organization","name":"Calithera Biosciences, Inc.","symbol":"CALA"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-11T16:00:57.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12 of the Option vests in each monthly installment as measured from June 9, 2020, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer.  In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to the Delphi Management Partners, VIII, L.L.C. (\"DMP VIII\") LLC Agreement, the Reporting Person is deemed to hold the options for the benefit of DMP VIII, which is entitled to hold the shares upon issuance. DMP VIII may be deemed the indirect beneficial owner of such shares, and the Reporting Person is a managing member of DMP VIII and may be deemed to share voting and dispositive power over shares held by DMP VIII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein."}],"balance_after":20000,"derivative":{"exercise_price":5.25,"expiration_date":"2030-06-08","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-20-016148","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496671/000089924320016148/doc4.xml","form_type":"4"}},{"id":3134938,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2020-05-26T20:24:03.000Z","date":"2020-05-21","kind":"grant","acquired":true,"shares":16400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 100% of the underlying shares on May 21, 2021, provided that the reporting person continues to serve as a director of the issuer through such date."}],"balance_after":16400,"derivative":{"exercise_price":19.11,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":16400},"source":{"system":"sec-edgar","filing":"0001209191-20-032011","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000120919120032011/doc4.xml","form_type":"4"}},{"id":3496935,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2019-06-07T12:59:28.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 100% of the underlying shares on June 6, 2020, provided that the reporting person continues to serve as a director of the issuer through such date."}],"balance_after":25000,"derivative":{"exercise_price":5.43,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-19-035378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000120919119035378/doc4.xml","form_type":"4"}},{"id":3504707,"issuer":{"id":113073,"kind":"organization","name":"Calithera Biosciences, Inc.","symbol":"CALA"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-03T16:06:42.000Z","date":"2019-05-30","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12 of the Option vests in each monthly installment as measured from May 30, 2019, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer.  In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to the Delphi Management Partners, VIII, L.L.C. (\"DMP VIII\") LLC Agreement, the Reporting Person is deemed to hold the options for the benefit of DMP VIII, which is entitled to hold the shares upon issuance. DMP VIII may be deemed the indirect beneficial owner of such shares, and the Reporting Person is a managing member of DMP VIII and may be deemed to share voting and dispositive power over shares held by DMP VIII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein."}],"balance_after":11000,"derivative":{"exercise_price":5.42,"expiration_date":"2029-05-29","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-19-015384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496671/000089924319015384/doc4.xml","form_type":"4"}},{"id":3551030,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-23T16:15:27.000Z","date":"2019-04-23","kind":"other","acquired":false,"shares":18940,"ownership":{"direct":false,"nature":"By Delphi BioInvestments VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC (\"Mereo\"), Mereo US Holdings Inc., Mereo Mergerco One Inc. (\"Merger Sub\") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the \"Merger\"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the \"Merger Consideration\") for each share of the Issuer's stock that they own."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. (\"DMP VIII\"), the general partner of each of Delphi Ventures VIII, L.P. and Delphi BioInvestments VIII, L.P. (collectively, the \"Delphi VIII Funds\"). As a managing member of DMP VIII, the Reporting Person shares voting and dispositive power over the shares held by the Delphi VIII Funds and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such shares held by the Delphi VIII Funds, except to the extent of her proportionate pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-19-010986","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000089924319010986/doc4.xml","form_type":"4"}},{"id":3551029,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-23T16:15:27.000Z","date":"2019-04-23","kind":"other","acquired":false,"shares":1991602,"ownership":{"direct":false,"nature":"By Delphi Ventures VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC (\"Mereo\"), Mereo US Holdings Inc., Mereo Mergerco One Inc. (\"Merger Sub\") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the \"Merger\"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the \"Merger Consideration\") for each share of the Issuer's stock that they own."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. (\"DMP VIII\"), the general partner of each of Delphi Ventures VIII, L.P. and Delphi BioInvestments VIII, L.P. (collectively, the \"Delphi VIII Funds\"). As a managing member of DMP VIII, the Reporting Person shares voting and dispositive power over the shares held by the Delphi VIII Funds and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such shares held by the Delphi VIII Funds, except to the extent of her proportionate pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-19-010986","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000089924319010986/doc4.xml","form_type":"4"}},{"id":3883968,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-25T18:10:33.000Z","date":"2018-06-22","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.55,"expiration_date":"2028-06-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-18-029842","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036118029842/doc1.xml","form_type":"4"}},{"id":3887008,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2018-06-20T20:08:14.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 100% of the underlying shares on June 19, 2019, provided that the reporting person continues to serve as a director of the issuer through such date."}],"balance_after":17000,"derivative":{"exercise_price":18.8,"expiration_date":"2028-06-18","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-18-038746","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000120919118038746/doc4.xml","form_type":"4"}},{"id":3908388,"issuer":{"id":113073,"kind":"organization","name":"Calithera Biosciences, Inc.","symbol":"CALA"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-04T16:09:18.000Z","date":"2018-05-31","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12 of the Option vests in each monthly installment as measured from May 31, 2018, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer.  In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to the Delphi Management Partners, VIII, L.L.C. (\"DMP VIII\") LLC Agreement, the Reporting Person is deemed to hold the options for the benefit of DMP VIII, which is entitled to hold the shares upon issuance. DMP VIII may be deemed the indirect beneficial owner of such shares, and the Reporting Person is a managing member of DMP VIII and may be deemed to share voting and dispositive power over shares held by DMP VIII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein."}],"balance_after":11000,"derivative":{"exercise_price":5.15,"expiration_date":"2028-05-30","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-18-014885","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496671/000089924318014885/doc4.xml","form_type":"4"}},{"id":3916947,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-25T17:16:25.000Z","date":"2018-05-23","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date."}],"balance_after":15000,"derivative":{"exercise_price":15.5,"expiration_date":"2028-05-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-18-033589","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118033589/doc4.xml","form_type":"4"}},{"id":4278863,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2017-06-16T20:50:42.000Z","date":"2017-06-15","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 100% of the underlying shares on June 15, 2018, provided that the holder continues to serve as a director of the issuer through such date."}],"balance_after":17000,"derivative":{"exercise_price":9.18,"expiration_date":"2027-06-14","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-17-040570","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000120919117040570/doc4.xml","form_type":"4"}},{"id":4283767,"issuer":{"id":113073,"kind":"organization","name":"Calithera Biosciences, Inc.","symbol":"CALA"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-13T16:37:07.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12 of the Option vests in each monthly installment as measured from June 9, 2017, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer.  In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to the Delphi Management Partners, VIII, L.L.C. (\"DMP VIII\") LLC Agreement, the Reporting Person is deemed to hold the options for the benefit of DMP VIII, which is entitled to hold the shares upon issuance. DMP VIII may be deemed the indirect beneficial owner of such shares, and the Reporting Person is a managing member of DMP VIII and may be deemed to share voting and dispositive power over shares held by DMP VIII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein."}],"balance_after":11000,"derivative":{"exercise_price":14.2,"expiration_date":"2027-06-08","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-17-016236","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496671/000089924317016236/doc4.xml","form_type":"4"}},{"id":4295572,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-02T17:48:43.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":3.3,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-17-023644","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036117023644/doc1.xml","form_type":"4"}},{"id":4302893,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-26T19:02:17.000Z","date":"2017-05-24","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date."}],"balance_after":15000,"derivative":{"exercise_price":16.9,"expiration_date":"2027-05-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-17-036029","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117036029/doc4.xml","form_type":"4"}}]}